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THE HYPOXIC CELL sensitizer Mison-
idazole (1-(2-nitroimidazole-1-yl)-3-meth-
oxypropan-2-ol, MISO) is currently under-
going worldwide trials of its clinical use-
fulness. Its primary dose-limiting toxicity
is peripheral sensory neuropathy (Wasser-
man et al., 1979) though encephalopathy is
occasional. There is no demonstrable dose
threshold for these effects, but the total
dose has generally been limited to 12 g/m2
(Dische et al., 1977; Urtasun, 1978) in an
attempt to reduce the toxicity to accept-
able levels.
There is evidence that the incidence of
neurotoxicity is related to the area under
the curve (AUC) of plasma drug concen-
tration against time (Dische et al., 1979)
or the "exposure index" as defined by
Dische, which is the product ofthe plasma
concentration in the plateau period and
the half-life. Potentially, a reduction in
AUC or "exposure index" might lead to a
lower incidence ofneurotoxicity. However,
since radiosensitization is dependent upon
the tumour concentration of MISO at the
time of irradiation (McNally et al., 1978;
Brown & Yu, 1980) high plasma levels
need to be maintained since these and
tumour concentration have been shown to
be similar in man (Dische et al., 1979; Ash
et al., 1979).
It has already been demonstrated that
pre-treatment with phenytoin shortens
the half-life of MISO in experimental
animals (Workman, 1979; White & Work-
man, 1980) and in patients given 2
large doses ofMISO separated by a 14-day
course of phenytoin (Workman et al.,
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1980). This has been explained by pheny-
toin stimulation of hepatic enzymes con-
cerned wit,h the metabolism of MISO. In
one small clinical study, dosing with
phenytoin appears to have reduced the
neurotoxicity (Wasserman et al., 1980).
This investigation was initiated after a
pilot study with MISO in advanced head
and neck cancers (Paterson et al., 1981) in
which there was a 5500 incidence of
peripheral neurotoxicity. Therefore it was
decided to examine phenytoin-induced
changes in the pharmacokinetics of MISO
in 13 patients, 8 with advanced squamous
cell carcinoma of the head and neck and 5
with advanced oesophageal tumours. All
patients received a conventional daily
course of external beam radiotherapy.
Seven patients received 0 5 g of MISO on
each treatment day, whilst the others
received 1 0 g on treatment days 1, 5, 10,
15, 20 and 25. MISO (Roche Products
Ltd) was given orally 3 to 4 h before
radiation treatment, whilst phenytoin
(phenytoin sodium BP) was given orally
in a dosage of 100 mg x 3 daily, including
weekends, but was started on Day 2 after
the initial base-line half-life of MISO had
been determined. No patients had ab-
normal liver function tests. No other drugs
known to interfere wit,h MISO metabolism
were given, and all patients gave full con-
sent for this investigation.
Blood samples (10 ml) were taken by
venepuncture immediately before drug
dosage and subsequently at various inter-
vals usually 1, 2, 3-4, 6, 12 and 23 h after
MISO dosage. Although 6 samples werePHARMACOKINETICS OF MISONIDAZOLE IN RADIOTHERAPY
normally taken on Day 1, on later occa-
sions only 3-4 samples per patient were
taken but these were always those between
irradiation time (3-4 h) and before the
next dose of MISO (23 h).
Blood samples were placed into lithium
heparin tubes and kept in a refrigerator
until the plasma was separated by centri-
fugation and stored in a deep freeze until
needed.
Plasma levels of MISO and its metabo-
lite desmethylmisonidazole (DEMIS) were
determined by reverse-phase high-per-
formance liquid chromatography (HPLC)
using a method similar to Workman et al.
(1978). For drug estimation 0'5 ml plasma
was placed in a centrifuge tube with a
known quantity of a standard (0.01 ml
Ro-07-0913, Roche Products Ltd) and
plasma proteins precipitated with 4-5 ml
Analar methanol. The clear supernatant
after centrifugation was injected into the
HPLC (LCUV detector, LCXPS pump
and PM 8251 recorder, Pye Unicam Ltd).
The separation was on a 10azm Partisil
ODS column, the UV spectrophotometer
set at 325 nm, the liquid phase was 20%
V/V methanol (BDH Chromatographic
grade) in distilled water and the flow rate
was 2 ml/min. The DEMIS, MISO and
standard Ro-07-091 3 appeared as peaks
at 135, 268 and 513 sec respectively. The
concentration of each compound was
determined as the peak height, which was
then related to the internal standard
Ro-07-0913.
The plasma levels were used to calculate
drug half-lives by linear-regression
analysis, using the highest plasma concen-
tration as the first point (always between
2 and 4 h) and the concentration before
the next day's dose (23 h) as the last point.
Half-life determinations were made on
Days 5, 8, 10, 15, 20 and 25. Of the 13
patients entered into this study, 2 were
withdrawn at Day 1]0, one developed a
MISO-induced rash and the other a
phenytoin arthropathy, but the results
for both patients up to Day 10 are in-
cluded in the analysis. Four patients were
taken off phenytoin at Day 8 and 2 at
Day 15, after each patient had already
shown a reduction in half-life for total
nitroimidazole (T-NITRO is a summation
of the concentration of MISO and
DEMIS) and MISO. The other 5 patients
remained on phenytoin throughout radi-
ation treatment. On 2 occasions a
patient did not take the MISO capsules,
and sometimes blood samples were not
collected by the ward staff. The mean
MISO and mean total T-NITRO concen-
trations at the time of irradiation (3-4h)
for patients receiving 0 5 or 1-0 g of MISO
are shown in Table I.
The concentrations of T-NITRO and
MISO at the time of irradiation (Table I)
throughout radiotherapy do not differ
significantly fromthe concentrations deter-
mined on Day 1, and neither radiotherapy
nor phenytoin had any effect. The greatest
t value is 1P05, with a corresponding
P = 0 4. The values in Table I are com-
parable with those determined for patients
TABLEI.-Plansma concentration ofdrug at irradiation and on subsequent days (mean + s.d.)
MAisoni(lazole 0-5 g/daily
Treatment day Ot
No. ofpatients 39
MISO (tLg/mi) 10:3 + 2-6
T-NITRO ([kg/ml) 12 5 + 3 1
MIjsonidazole 1 g/5 days
Treatment clay 0
No. ofpatients 32
MISO (p,g/mi) 18 8+ 4 4
T-NITRO (/ig/ml) 21-9 + 3-4
I
7
10-4+3 1
114+34
6
206 + 32
22 0+ 3 7
5
6
109+3 1
137 + 3*5
5
6
19 _2+7
222 + 36
8
7
9 6+2 3
12-7 + 28
10
6
18-8+2-8
22 1 + 37
10
6
9 8+2-6
13 4+3 4
15
4
186+2 1
224+4 1
* Poole(I data of 4 patients measurement on Day 20 and .3 on Day 25.
t At time of irra(liation.
15
5
10(1 + 36
12 4+3-6
20
5
21-0+4 1
23 6+3-6
25*
7
10.5+ 14
129+ 1-6
25
5
17-9+3-8
20 4+2-8
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TABLE II.-Drug half-lives expressed as apercentage ofthe value on Day 1 (mean +standard
deviation (n) =patient number)
Total nitroimi(lazole. Mean lhalf-life, on Day 1 10-1 + 1-6 h (13)
Treatment (lay 5 8 10
No. of patients 12 7 8
Daily phenytoin 77-6+ 12-8 76-0+ 10-3 72-5+ 11-9
t; P 6-06; 0-0001 6-16; 0-001 6-54; 0-0005
Phenytoin withdlrawn
Day 8t
t; P
15
6
72-6 + 8-9
6-88; 0-003
20
5
82-7+ 18-1
2-20; 0-1
25
3
81-6+ 15-5
2-06; 0-2
82-2+ 8-5 99-6 + 9-9 97-5+25-7 *101-8+20-4
4-19; 0-03 0-08; 0-9 0-19; 0-9 0-29; 0-8
Misonidazole. Mean half-life on Day 1: 8-92 + 1-3 (13)
Treatment day 5 8
No. of patients 12 7
Daily phenytoin 71-4+ 13-2 63-3+8-4 67
t;P 7-51; 0-00001 11-6; 0-0001 5-7
Phenytoin witlh(lrawn
Day 8t
t; P
10
8
'-4+ 11-2
71; 0-001
15
6
63-2 + 10-8
8-35; 0-0005
20
5
72-1 + 16-8
3-71; 0-02
25
3
74-2+ 19-5
2-29; 0-15
67-8 + 6-5 98-9 + 16-3 94-1 + 20-7 *100 5+21-1
9-91; 0-003 0-13; 0-9 0-57; 0-6 0-08; 0-9
* Pooled data from 11 patients whio ha(d phenytoin witlhdrawn for 7 days or longer.
t Results from 4 patients.
TABLE III.-Concentration of Desmethyl-MISO as percentage of total nitroimidazole at
time of irradiation (mean+s.d.)
Tieatment clay
No. of patients
DEMIS
t; P
No. of patients
Phenytoin witlhdrawn
Day 8
1 5
13 12
7-12+ 3-2 17-6+ 7-0
4-88; 0-0001
8/10* 15 20 25
10 6 4 3
20-5+9-5 18-8+5-6 21-1 + 7-0 18-1+5-8
4-77; 0-0002 5-83; 0-00002 5-76; 0-00002 4-65; 0-00004
4 4 12
18-0+4-6 17-9+3-4 t16-6+5-8
t;P 5.
* Patients monitored at Days 8 an(d 10 were pooled.
t Patients who ha(d phenytoin withdrawn for 7 clays or longer.
receiving MISO at 0-6 and 1-2 g/m2 in of the or
other clinical trials at this centre, i.e. a cantly Ic
T-NITRO of 23-4 + 3-7 ,ug/ml (12 patient values o
measurements) and 48-1 + 10-6 /g/ml (18 shown i
patient measurements) respectively. stopped
As different doses of MISO were used value at
the half-lives of both MISO and T- (e.g. 0-9
NITRO, as determined by linear regres- half-life
sion on Day 1, were normalized to 100. of its va
The reductions in half-life of MISO and that for
T-NITRO induced by phenytoin are 1199% (I
shown in Table II. These reductions are Table
accompanied by an increase in the con- of the n
centration of DEMIS and the changing Days 5 t
proportion of the metabolite as a percent- on Day
age of the T-NITRO (as shown in Table before p
III) (Workman, 1979; White & Workman, tion of
1980; Workman et al., 1980). Daily T-NITR
phenytoin significantly reduced the half- (3-4 h) I
life of both MISO and T-NITRO. The 8-10 (P
mean half-lives, expressed as a percentage crease. I
40; 0-0001 5-82; 0-00004 5-12; 0-00004
riginal value on Day 1 are signifi-
)wered by the phentyoin, with P
f the order of 0-001 (t test) as
n Table II. When phenytoin is
the half-lives soon return to the
Day 1 with an insignificant P
at Day 15). By Day 8 the mean
ofMISO had fallen to 63-3 + 8-4%
tlue on Day 1 (P=0-0001) while
T-NITRO was reduced to 72-5 +
P= 0-001) ofits Day 1 value.
III shows that all measurements
nean concentration of DEMIS on
to 25 are significantly higher than
1 (P= 0-001 by t test). On Day 1,
henytoin, the plasma concentra-
DEMIS was 7-12 +3.2% of the
' O at the time of irradiation
but it rose to 20-5 + 950o at Days
=0-0002), a highly significant in-
kn unexpected finding also shown
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in Table III was the failure of the propor-
tion of DEMIS to fall in those patients in
whom phenytoin was stopped at Day 8
despite the fact that the half-lives of
MISO and T-NITRO returned to a value
similar to that measured on Day 1.
By Day 5 the mean reduction in half-
life of MISO was 28.4%, with a maximum
of 3688% being reached by Day 15, whilst
the values for T-NITRO on those days
were 24% and 27.6% respectively. These
results are in close agreement with the
310% seen for MISO by Workman et al.
(1980). At Day 1 DEMIS constitutes
7a1200 of the T-NITRO present in the
plasma (Table III) and this compares well
with the values obtained at this centre
with 0 6 g/m2 MISO given daily (9.06 +
2.6%, mean of 13 patients) and 12 g/m2
MISO (8.35 + 204%, mean of 17 patients)
given 3 times weekly. It is also similar to
the value of 110% reported by Workman
et al. (1980). By Day 5 the proportion of
DEMIS (at time of irradiation 3-4 h) rose
to 17.6% and reached a maximum value
of 210% during phenytoin dosage, which is
comparable to the 170 after 14 days
treatment with phenytoin reported by
Workman et al. (1980).
At 20-23 h after the first dose of MISO,
the metabolite DEMIS constituted 22-5 +
8.8% (13 patients) of the T-NITRO on
Day 1, but this rose substantially to
51-1 + 13.9% (13 patients) at Days 8-10 if
the results on both these days are pooled.
In 5 ofthe 7 patients who received daily
MISO, it was possible to compare T-
NITRO levels at 2 h and at the time of
irradiation (3-4 h after dosing). On Day 1
the plasma concentration of T-NITRO
was 14-0 + 2-4 ,ug/ml at 2 h and 12-8 + 1-6
,ug/ml at irradiation. By Day 8 these
plasma values were 16-4 + 2-9 jug/ml and
13-5 + 2-6 jug/ml respectively, and though
the differences are not large they are in
agreement with the conclusion of Work-
man et al. (1978) who also observed higher
concentrations at 2 h.
The major dose-limiting toxicity of
MISO remains its neurotoxicity, for which
the concomitant use of phenytoin has
been suggested as a means of reducing
this effect (Wasserman et al., 1980;
Workman et al., 1980). This study has
demonstrated the time-course of the
phenytoin-induced change in the phar-
macokinetics ofMISO inpatientsreceiving
radical radiotherapy, and it has shown
that the half-life of both T-NITRO and
MISO are significantly reduced by it.
Additionally, the plasma concentrations
of these drugs at the time of irradiation
have not been significantly reduced, sug-
gesting that tumour concentrations and
so radiosensitization are not altered. The
reduction in the half-life of T-NITRO is
interesting in relation to the possible use
of DEMIS as a radiosensitizer, though it
has recently been shown to produce a
similar level of neurotoxicity to MISO in
baboons (Lennox-Smith, personal com-
munication) and in man (Dische et al.,
1981).
XVe wish to thank Dr I. Lennox-Smith of Roche
Products Ltd for supplies of Misonidazole, Mr C. A'.
Smith for help with the statistical analysis, and the
radiographers at Velindre Hospital, whose support
is essential in such clinical investigations.
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